

## INDEX TO VOLUME 86

- Abbot, J. V., 507–511
- Actinobacillus actinomycetem comitans* complicating thoracic actinomycosis, 341–343
- Actinobacillus* infection, thoracic, 53–54
- Adhesion molecules, 455–457
- $\beta$ -Agonists in asthma, 471–476, 477–479
- AIDS-associated lymphocytic interstitial pneumonitis, 49–52
- AIDS and mycobacterial disease, 491–494
- Air pollution, indoor, 225–235
- Airways lability predictors in the elderly, 27–32
- Airway narrowing, acute; determinants of severity, 391–396
- Airways obstruction in children, mean transit time as indicator, 301–304
- Aitken, M. L., 211–214
- Alexander, F., 485–490
- Allen, F., 121–124
- Allen, M. B., 165–166, 445
- Allergic bronchopulmonary aspergillosis, 441–442
- Alveolar-septal amyloidosis, 345–347
- Amoxycillin in lower respiratory infections, 157–160
- Amyloidosis, alveolar-septal; radiographic presentation, 345–347
- Angiotensin II, 21–26
- Anti-neutrophil cytoplasmic antibodies, 367–369
- Aprile, C., 327–333
- Arthropathy, acute, in mediastinal tuberculosis, 57–59
- Asian patients, increased admission rates in, 297–300
- Askari, A., 57–59
- Asthma
- acute, 101–104
  - acute, severe, 215–218, 495–497
  - admission rates in Asian patients, 297–300
  - $\beta$ -agonists in, 471–476, 477–479
  - airway narrowing in, 391–396
  - cardiovascular effects of therapy, 419–423
  - cortisol stress response, 495–497
  - cytokines in, 375–389
  - eosinophils in, 101–104, 375–389
  - exercise capacity, in men, 151–155
  - fenoterol, 419–423
  - functional upper airway obstruction presenting as, 513–516
  - and hyperventilation tetany, 349–351
  - hypokalaemic effects of therapy, 419–423
  - incidence in 4–11 year old children, 403–407
  - ipratropium bromide, 151–155, 215–218
  - mild, 349–351
  - nebulizer therapy, 105–108, 151–155, 215–218, 419–423
  - nedocromil sodium, 311–316
  - oral high frequency oscillations, 211–214
  - patient education and self-management, 358–359
  - peak flow measurement, 358–359
  - platelet activating factor in, 375–389
  - pulmonary function, 211–214
  - radiographer's, 167–169
  - referral to hospital specialist, 358
  - risk factor for relapse, 101–104
  - salbutamol, 419–423
  - serious, 357
  - special treatment, 357
  - steroid therapy, 105–108, 495–497, 528–529
  - terbutaline, 215–218
  - vascular factors, 179–181
  - see also* Childhood asthma; Chronic asthma
- Audit, use of erythromycin, 503–505
- Austwick, P. K. C., 225–235
- Ayres, J. G., 358, 403–407
- Bacchella, L., 327–333
- Ballerin, L., 174–175
- Balter, M. S., 441–442
- Barter, C. E., 425–429
- Bass, C., 349–351
- Beasley, R., 419–423
- Bernstein, A., 317–325
- Bilton, D., 507–511
- Bleomycin-induced lung damage, 327–333
- Blood eosinophil count, 101–104
- Blundell, G., 495–497
- Boothroyd, A. E., 39–44
- Bouros, D., 219–223
- Bowker, C. M., 53–54
- Bremner, P., 419–423
- Brewis, R. A. L., 359
- Bright, P., 528
- British Association for Lung Research, Abstracts of 11th Summer Meeting, 531–543
- British Thoracic Society Research Committee, 7–13, 15–19
- Bromhexine, 157–160
- Bronchial hyperresponsiveness, 179–181
- Bronchial washings in diagnosis of invasive pulmonary aspergillosis, 243–248
- Bronchiectasis
- chest physiotherapy, 109–114
  - humidification, 109–114
  - inhaled steroids treatment, 121–124, 529
  - progression, radiological evidence, 397–401
- Bronchoalveolar lavage, diagnosis of invasive pulmonary aspergillosis, 243–248
- Brown, P. H., 495–497
- Bryan, A. J., 437–440
- Bulgheroni, A., 327–333
- Bullock, A., 105–108
- Burchardi, H., 517–519
- Burgess, C., 419–423
- Bush, A., 161–164
- Butler, N., 403–407
- Campbell, B., 201–203
- Cancer
- plasma cell granuloma, 161–164
  - SCCAg as tumour marker, 201–203
  - symptomatic hypercalcaemia in, 359–360
  - synovial cell sarcoma, 357–358
  - see also* Lung cancer
- Capewell, S., 485–490, 499–502
- Captopril, 21–26
- Caraco, Y., 521–523
- Carbon monoxide transfer factor in HIV-infected patients, 253–256
- Cardiovascular effects of therapy, 419–423
- Cayton, R. M., 151–155
- Chan S. L., 115–119
- Chapman, B. J., 485–490
- Chemotherapy for lymph node tuberculosis, 15–19
- Chen, Y. M., 249–251
- Chetty, M. C. P., 317–325
- Childhood asthma, incidence in 4–11 year olds, 403–407
- Children
- surgical emphysema, 529–530
  - mean transit time in, 301–304
  - pneumothorax, 529–530
  - pre-term, and inhaled sodium cromoglycate, 131–134
- Chopra, M. P., 57–59, 446–447
- Chronic airflow limitation, home nebulizer therapy, 33–38, 446–447
- Chronic asthma
- high dose steroid treatment, 105–108, 528–529
  - nedocromil sodium management, 311–316
  - steroid-dependent, 105–118, 528–529
- Chronic bronchitis, *N*-acetylcysteine treatment, 89–92
- Clancy, L., 481–484, 491–494
- Clarke, J., 121–124
- Clubbing and thermography, 257–259
- Coggon, D., 27–32
- COLD, terbutaline, inhaled, 93–96, 527–528

- Cole, P. J., 397–401  
 Computed tomography *see* CT  
 Connellan, S. J., 53–54  
 Connolly, C. K., 451–453  
 Conway, J. H., 109–114  
 COPD, acute airway narrowing, 391–396  
 Coronary artery bypass surgery, 195–199  
 Corticosteroids, 441–442  
 Cortisol stress response, 495–497  
 Costello, J., 477–479  
 Cough  
   chronic, persistent, 425–429  
   ipratropium bromide, 425–429  
   persistent, in SE England, 143–149  
 Crane, J., 419–423  
 Crisp, A., 165–166  
 Critically ill patients, oxygen transport in, 289–295  
 Crompton, G. K., 485–490, 495–497  
 Crozier, T. A., 517–519  
 CT  
   extrinsic allergic alveolitis, 135–141  
   unexplained haemoptysis, 39–44  
 Cullinan, P., 143–149  
 Cundall, D. B., 445–446  
 Cunningham, D. A., 253–356  
 Currie, D. C., 397–401  
 Cystic fibrosis  
   adolescent, 45–48  
   adult, 45–48  
   exacerbation after holidays at high altitude, 55–56  
   exercise and physiotherapy, 507–511  
   infective pulmonary exacerbation, 45–48  
   spirometry, 45–48  
 Cytokines in asthma, 375–389
- Davies, A., 125–130  
 Davies, A. J., 503–505  
 Davies, R. J., 167–169  
 de Berker, D., 61–62  
 Dilworth, J. P., 205–210  
 Disseminated tuberculosis, multiple organ failure in, 517–519  
 Dodd, M. E., 507–511  
 Donegan, C., 253–256  
 Dornely, S. M., 525–526  
 Dow, L., 27–32  
 Drennan, C., 311–316  
 Dueholm, M., 89–92  
 Dussek, J. E., 1–2  
 Dyspnoea and terbutaline, 93–96, 527–528
- Edwards, D., 39–44  
 Elborn, J. S., 121–124, 529  
 Elderly populations; respiratory symptoms as predictors of airways  
   labiality, 27–32  
 Emphysema revisited (Symposium), 187–193  
 End-tidal  $PCO_2$  and hypocapnic symptoms, 335–340  
 Eosinophils, 375–389  
 Eosinophil blood count, 101–104  
 Eosinophilic granuloma, 61–62  
 Epstein-Barr virus antibodies, 49–52  
 Erslev, A. J., 261–263  
 Erythromycin, 503–505  
 Escarrabill, J., 269  
 Estopa, R., 269  
 Evald, T., 89–92, 93–96, 527–528  
 Evans, J. M., 237–241  
 Evans, T. W., 289–295  
 Exercise in cystic fibrosis treatment, 507–511  
 Exercise capacity in asthma, 151–155  
 Extrinsic allergic alveolitis, 135–141
- Fenoterol, 419–423  
 Ferraris pocket peak flow meter, 525–526  
 FEV<sub>1</sub>, 93–96, 451–453, 525–526, 527–528  
 FitzGerald, J. M., 358–359  
 FitzGerald, M. X., 277–282  
 Fleming, J., 253–256  
 Fleming, J. S., 109–114  
 Flower, C. D. R., 135–141  
 Fludarabine monophosphate, 261–263  
 Forman, S. J., 243–248  
 Freeman, W., 151–155  
 Freeth, M. G., 53–54  
 French, P. D., 253–256  
 Functional upper airway obstruction presenting as asthma, 513–516  
 FVC and terbutaline, 93–96, 527–528
- Galimberti, M., 327–333  
 Ganderton, D., 237–241  
 Gardner, W. N., 273–275, 335–340, 349–351  
 Giorshve, C., 257–259  
 Goldman, J. M., 33–38  
 Goswami, R., 157–160  
 Greening, A. P., 485–490, 495–497  
 Greenough, A., 97–100, 131–134
- Haemoptysis, unexplained; role of CT, 39–44  
 Han, L. Y., 397–401  
 Hansen, N.-C., 89–92  
 Hara, N., 431–436  
 Harris, J. R. W., 253–256  
 Harrison, J., 225–235  
 Healy, E., 491–494  
 Heap, D. C., 167–169  
 Herala, M., 101–104  
 Herdman, M. J., 167–169  
 Hetzel, M. R., 39–44  
 Higenbottam, T., 105–108, 471–476, 528–529  
 Higgs, C. M. B., 367–369  
 High frequency oral oscillations, and asthma, 211–214  
 High-frequency ventilation, 125–130  
 HIV-infected patients, low carbon monoxide transfer factor in,  
   253–256  
 Hodson, M. E., 45–48, 55–56  
 Holgate, S. T., 27–32, 109–114  
 Holidays at high altitude; cystic fibrosis exacerbation, 55–56  
 Holmes, P. W., 425–429  
 Holst, P., 311–316  
 Horak, D. A., 243–248  
 Hudson, M., 301–304  
 Hudson, N. E., 125–130  
 Hughes, D. T., 525–526  
 Hughes, P., 481–484  
 Humidification, 109–114  
 Hypercalcaemia in lung cancer, 359–360  
 Hyperventilation syndromes, 273–275  
 Hyperventilation tetany due to mild asthma, 349–351  
 Hypocapnic symptoms and end-tidal  $PCO_2$  in normal subjects,  
   335–340  
 Hypokalaemic effects of therapy, 419–423  
 Hypoxic lung disease, stable, 21–26
- Immunoglobulin G subclass levels, 3–5  
 Inhaler therapy: a clinically relevant modification, 237–241  
 Inspiratory mouth pressure and respiratory muscle activity, 305–309  
 Intensive care unit; community-acquired pneumonia, 7–13  
 Intravenous drug users; AIDS and mycobacterial disease, 491–494  
 Invasive pulmonary aspergillosis; diagnosis, 243–248  
 Ipratropium bromide, 151–155, 215–218, 425–429  
 Ishida, T., 431–436
- Janson, C., 101–104  
 Javaid, A., 151–155  
 John, P. J., 157–160
- Faragher, E. B., 225–235  
 Feldman, C., 3–5

- Johnston, B., 121–124  
 Jolley, A. E., 503–505  
 Jones, D., 311–316  
 Jones, D. J., 283–287  
 Juniper, M. E., 1–2
- Kane, G. C., 261–263  
 Kaneko, S., 431–436  
 Kassem, N., 237–241  
 Kay, E. A., 317–325  
 Keittelmann, S., 93–96  
 Kelly, P., 481–484, 491–494  
 Kendall, S. W. H., 365–366, 437–440  
 Kortsik, C., 375–389  
 Kramer, M. R., 49–52  
 Kroegel, C., 375–389, 455–457  
 Kyi, T., 57–59
- Lange, P., 93–96  
 Large, S. R., 437–440  
 Lawton, L., 225–235  
 Lee, J., 115–119  
 Lee, P. Y., 249–251  
 Leitch, A. G., 173, 371–373, 445, 527  
 Levinson, H., 257–259  
 Levy, H., 243–248  
 Liippo, K., 359–360  
 Little, S. A., 225–235  
 Lockhart, A., 179–181  
 Low, D., 403–407  
 Lower respiratory infections  
   bromhexine treatment, 157–160  
   community-acquired, 503–505  
   erythromycin treatment, 503–505  
 Luisetti, M., 327–333  
 Lung cancer  
   primary carcinomas, 521–523  
   pulmonary tuberculoma, 431–436  
   and recurrent venous thrombosis, 521–523  
   respiratory tract epithelium and neoplasia, 531–543  
   in young patients, 499–502  
 Lung damage, bleomycin-induced, 327–333  
 Lung function, neonatal RDS, 97–100  
 Lymph node tuberculosis, 15–19  
 Lymphocytic interstitial pneumonitis associated with AIDS, 49–52
- McGarry, J., 121–124  
 McLeod, D. T., 503–505  
 McMichael, A. J., 261–263  
 Madsen, H. D., 89–92  
 Mahashur, A. A., 157–160  
 Maher, J., 481–484  
 Maltbaek, N., 89–92  
 Maltezas, G., 219–223  
 Manresa, F., 269  
 Mantoux test, 219–223  
 Marshall, A. J., 345–347  
 Marshall, S., 419–423  
 Matthews, A., 21–26  
 Matthys, H., 375–389, 455–457  
 Mean transit time as indicator of airways obstruction in children, 301–304  
 Mediastinal tuberculosis, acute arthropathy in, 57–59  
 Microbial indoor air pollution, 225–235  
 Millar, A. B., 39–44  
 Mitchell, D. M., 253–256  
 Monasterio, C., 269  
 Moores, C., 125–130  
 Morgan, R. A., 345–347  
 Morrison, J. F. J., 215–218  
 Mortality predictors in silicosis, 115–119  
 Moxham, J., 237–241, 349–351  
 Mucklow, E. S., 529–530
- Mucus, bronchial, effect of high-frequency ventilation on non-Newtonian properties, 125–130  
 Muers, M. F., 33–38, 215–218  
 Mulcahy, F. M., 491–494  
 Munro, N. C., 397–401, 529  
 Mycobacterial disease and AIDS, 491–494  
*Mycobacterium avium intracellulare* pulmonary infection in eosinophilic granuloma, 61–62  
 Myers, P., 297–300
- N*-acetylcysteine, 89–92  
 Nebulizer therapy  
   in asthma, 105–108, 151–155, 215–218, 419–423  
   at home, 33–38, 317–325, 446–447  
   long-term assessment, 317–325  
 Necrotizing fasciitis, 249–251  
 Nedocromil sodium  
   in chronic asthma, 311–316  
   dosage frequencies, 311–316  
 Neonatal respiratory distress syndrome, 97–100  
 Ng, G. Y., 305–309  
 Ng, T. P., 115–119  
 Nielsen, H., 89–92  
 Ninan, T., 301–304  
 Niven, R. McL., 513–516  
 Nolan, K. M., 525–526  
 Noone, P., 341–343
- Obstructive airways disease, 409–417  
 O'Connor, C. M., 277–282  
 O'Driscoll, B. R., 317–325  
 Organ failure, multiple, in disseminated tuberculosis, 517–519  
 Oropharyngeal carrier state, abnormal, 183–186  
 Ormerod, L. P., 297–300  
 Otulana, B. A., 105–108  
 Oxygen, portable, 269  
 Oxygen transport in the critically ill, 289–295  
 Øyri, A., 357
- Packe, G. E., 45–48  
 Page, C., 477–479  
 Page, R. L., 165–166  
 Pallarés, L. C. M., 289–295  
 Palmer, J. B. D., 409–417  
 Pansari, S., 403–407  
 Parry, G. W., 1–2  
 Particulate indoor air pollution, 225–235  
 Patel, J. M., 57–59  
 Paterson, I. C., 61–62  
 Patrick, H., 261–263  
 Peacock, A. J., 21–26  
 Peak flow meter, 451–453, 525–526  
 Pearce, N., 419–423  
 Pearson, S. B., 215–218, 445–446  
 PEF, 525–526  
 Penn, O. C. K. M., 195–199  
 Perng, R. P., 249–251  
 Perring, S., 109–114  
 Physiotherapy  
   in bronchiectasis, 109–114  
   in cystic fibrosis treatment, 507–511  
 Pickering, C. A. C., 225–235, 513–516  
 Pierce, R. J., 425–429  
 Pierson, D. J., 211–214  
 Pitchenik, A. E., 49–52  
 Pizzini, L., 327–333  
 Plasma cell granuloma; spontaneous arrest, 161–164  
 Platelet activating factor, 375–389  
 Pleural effusions; thoracoscopy, 437–440  
 Pneumomediastinum, 530  
 Pneumonia  
   aetiology, 7–13  
   community-acquired, 7–13, 174–175

- intensive care unit, 7–13  
management, 7–13, 459–469  
routine microbial investigation, 174–175
- Pneumonitis, 'smoke-bomb', 165–166
- Pneumothoraces from synovial cell sarcoma, 357–358
- Pneumothorax, 529–530  
spontaneous; surgical intervention, 1–2
- Portable oxygen therapy, 269
- Postoperative chest infection; problem for smokers, 205–210
- Postoperative pulmonary function abnormalities, 195–199
- Potena, A., 174–175
- Prescribed respiratory diseases in the 1990s, 283–287
- Prichard, J. S., 341–343
- Public Health Laboratory Service, 7–13
- Pulmonary alveolar-septal amyloidosis; radiographic presentation, 345–347
- Pulmonary eosinophilia with systemic features, 485–490
- Pulmonary function  
oral high frequency oscillations, 211  
postoperative abnormalities, 195–199
- Pulmonary haemodynamics, 21–26
- Pulmonary malignancy, SCCAg as tumour marker, 201–203
- Pulmonary *Mycobacterium avium intracellulare* infection in eosinophilic granuloma, 61–62
- Pulmonary toxicity and fludarabine monophosphate, 261–263
- Pulmonary tuberculoma, 431–436
- Puolijoki, H., 359–360
- Putinati, S., 174–175
- Putterman, C., 531–532
- Radiographer's asthma, 167–169
- Radiographic analysis of pulmonary tuberculoma, 431–436
- Radiological evidence of progression of bronchiectasis, 397–401
- Rafferty, G. F., 335–340
- Ramos, M., 49–52
- Rea, H., 311–316
- Rebuck, A. S., 441–442
- Regnard, J., 279–281
- Respiratory disease and adhesion molecules, 455–457
- Respiratory distress syndrome, neonatal, 97–100
- Respiratory failure, acute, and fludarabine monophosphate, 261–263
- Respiratory muscle activity and inspiratory mouth pressure, 305–309
- Respiratory symptoms, high incidence in 4–11 year old children, 403–407
- Respiratory tract epithelium and neoplasia, 531–543
- Rimmer, S. J., 55–56
- Ring, N. J., 345–347
- Roberts, T., 513–516
- Rush, P. J., 257–259
- Russell, G., 301–304
- Saisch, S. G. N., 335–340
- Salbutamol, 419–423
- Saldana, M. J., 49–52
- Salmeterol, 409–417
- Sankaran, R., 499–502
- Sarcoidosis, 277–282
- Sarcoma, synovial cell, 357–358
- Sartori, S., 174–175
- Schauer, A., 517–519
- Schneerson, J. M., 135–141
- Selby, C. D., 445
- Shaheen, M. Z., 65
- Sharma, R. R., 157–160
- Shaw, R. J., 253–256
- Shepherd, G. L., 409–417
- Sheppard, M. N., 161–164
- Shore, A., 257–259
- Siafakas, N., 219–223
- Sick building syndrome, 225–235
- Silicosis, mortality predictors, 115–119
- Simer, L., 521–523
- Sindrup, J. H., 93–96
- Sivner, A. L., 446–447
- Skin anergy and tuberculosis, 481–484
- Smith, C., 3–5
- 'Smoke-bomb' pneumonitis, 165–166
- Smokers; postoperative chest infection problems, 205–210
- Snell, N. J. C., 357–358
- Snook, N., 165–166
- Sodium cromoglycate, 131–134
- Speechly-Dick, M. E., 55–56
- Spirometry, changes; infective pulmonary exacerbation in cystic fibrosis, 45–48
- Sputum  
amoxycillin levels, 157–160  
and persistent cough, in SE England, 143–149
- Squamous cell carcinoma antigen (SCCAg), 201–203
- Sterk, P. J., 391–396
- Steroid-dependent asthma, 105–108, 528–529
- Steroids, 65  
asthma treatment, 105–108, 495–497, 528–529  
in bronchiectasis, 121–124, 529  
and cortisol stress response, 495–497
- Stewart, S., 135–141
- Stokes, M. J., 305–309
- Stoutenbeek, C. P., 183–186
- Strickland, B., 397–401
- Strunin, L., 525–526
- Stuart, A. M., 409–417
- Su, W. J., 249–251
- Sudlow, M. F., 499–502
- Sugimachi, K., 431–436
- Sugio, K., 431–436
- Surgical emphysema, 529–530
- Swan, D., 358–359
- Syabbalo, N., 173–174
- Sydow, M., 517–519
- Sykes, A., 403–407
- Synovial cell sarcoma, 357–358
- Tadmor, B., 521–523
- Tasker, V. S., 157–160
- Taylor, E., 446–447
- Taylor, R. J., 317–325
- Teale, C., 33–38, 215–218, 445–446
- Tegtmeier, B. R., 243–248
- Terbutaline, 93–96, 215–218, 527–528
- Tetley, T. D., 187–193
- Thermography, use in clubbing, 257–259
- Thomson, A. M., 446
- Thoracic actinobacillus infection, 53–54
- Thoracic actinomycosis complicated by *Actinobacillus actinomycetum comitans*, 341–343
- Thoracoscopy, 365–366, 437–440
- Thornley, P., 311–316
- Thorshauge, H., 89–92
- Torres, A., 183–186
- Tracheo-bronchial clearance, 109–114
- Transpulmonary angiotensin II formation, 21–26
- Trevisani, L., 174–175
- Trigg, C. J., 167–169
- Tube thoracostomy, 249–251
- Tuberculin skin tests, 219–223
- Tuberculoma, pulmonary, 431–436
- Tuberculosis  
chemotherapy, 15–19  
compliance with treatment, 173–174  
contact tracing, 173, 371–373, 445–446  
disseminated, 517–519  
and HIV infection, 491–494  
of lymph nodes, 15–19  
mediastinal, 57–59  
relapse, 173–174  
and skin energy, 481–484
- Tumour marker, 201–203

- 
- Turner, M. O., 358–359  
Twentyman, O. P., 471–476  
Tyrrell, J., 341–343  
Tzanakis, N., 219–223  
Tzortzaki, E., 214–223
- Upham, J., 201–203  
Upper abdominal surgery, 205–210  
Upper airways obstruction, functional, 513–516  
Upper respiratory tract infection, 425–429
- van Belle, A. F., 195–199  
Van Saene, H. K. F., 183–186  
Varghese, G., 121–124  
Varma, N., 105–108  
Vascular factors, 179–181  
Venous thrombosis, recurrent, as presenting sign of lung cancer, 521–523  
Villani, F., 327–333  
Vincent, J. M., 135–141, 211–214  
Virchow, J. C., Jr, 375–389  
Viskum, K., 409–417
- Wadee, A., 3–5  
Wahn, U., 161–164  
Walking distance, 93–96, 527–528  
Ward, A. J. M., 237–241  
Warner, J. O., 161–164  
Wathen, C. G., 499–502  
Weatherby, H., 317–325  
Webb, A. K., 507–511, 513–516  
Weller, P. H., 403–407  
Wells, A., 311–316  
Wells, F. C., 365–366, 437–440  
Wesseling, G. J., 195–199  
White, R. J., 205–210  
Williams, J., 403–407  
Windebank, W. J., 65  
Woodhead, M. A., 459–469  
Woodman, K., 419–423  
Wouters, E. F. M., 195–199  
Wu, M. F., 249–251
- Yokota, S. B., 243–248  
Yokoyama, H., 431–436  
Yuksel, B., 97–100, 131–134
- Zwi, S., 3–5